Category: Neuromyelitis optica spectrum disorders

CHMP backs expanded indications for Uplizna in NMOSD, IgG4-RD and gMG

The Committee for Medicinal Products for Human Use has adopted a positive opinion recommending an extension to the marketing authorisation for Uplizna, also known as inebilizumab, broadening its use across three immune-mediated neurological and systemic conditions. The opinion, adopted on 11 December 2025, supports new indications for Uplizna in neuromyelitis optica spectrum disorders, immunoglobulin G4-related…